Latest Scientific Collaboration News

Temas Resources has fortified its position in the critical minerals sector through key strategic moves including joining Québec’s CSM Scientific Network, engaging market-making services, and commissioning independent equity research.

Nyrada has completed its Phase I trial for Xolatryp, confirming safety and predictable pharmacokinetics, while securing AU$8.25 million to fund an upcoming Phase IIa trial targeting heart attack patients.

Bellavista Resources reports promising initial bioleaching results from its Brumby Project, confirming recovery of key critical minerals and advancing plans for bulk sample testing.

Clarity Pharmaceuticals reports a robust cash position and strategic refocus on its lead prostate cancer asset, Cu-SAR-bisPSMA, supported by multiple FDA Fast Track designations and advancing clinical trials.